Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable.
A narrow question about Reading a rodent study, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
The arithmetic in post #3 is right; the assumption feeding it is the part to check.
Offering a way to settle Reading a rodent study rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
If you are new and reading this thread for the answer to Reading a rodent study: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Adding a data point of agreement rather than a data point.
Everything in post #3 holds. The case it does not cover is the one I have.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
Narrowing post #7, because the general version has more than one answer.
My position on Reading a rodent study is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
I had written a reply contradicting post #7 and deleted it. Here is what survived.
What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.
Confirming post #7 from a second method, which matters more than confirming it from a second person.
My understanding of Reading a rodent study is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
The pulsatile character of endogenous growth hormone release is why a secretagogue and exogenous growth hormone are not interchangeable, and why a single measured level tells you very little about either.
Growth hormone secretagogues act on the ghrelin receptor or on the growth hormone releasing hormone receptor rather than supplying growth hormone, which is the distinction that matters for anyone reading the literature.
Post #12 is the version of this I will quote in future. One addition.
What I would want before treating Reading a rodent study as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
I have no interest in any supplier named above.
CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
Taking Reading a rodent study seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Post #15 put the caveat in the right place and I want to underline it.
Marking my uncertainty on Reading a rodent study explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Post #16 answers the question as asked. The question underneath it is different.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
Adding the caveat now so it does not have to be extracted later.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
Noting that I have skin in this question and have tried to discount for it.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
The version of Reading a rodent study that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
I read post #19 twice before replying, because I had assumed the opposite.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
The conclusion is tentative; the arithmetic underneath it is not.
Nothing to add on the substance. Thank you for taking the question at face value.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
The disagreement above is smaller than it looks once the terms are fixed.
Post #27 is right about the mechanism and I think understates the practical bit.
Filing a mild objection to the consensus on Reading a rodent study. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Post #27 put the caveat in the right place and I want to underline it.
CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.
Caveat: everything above assumes the paperwork is what it says it is.
Building on post #27 rather than restating it.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
That distinction has done more work for me than anything else in this category.